<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655964</url>
  </required_header>
  <id_info>
    <org_study_id>3418</org_study_id>
    <nct_id>NCT03655964</nct_id>
  </id_info>
  <brief_title>Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke</brief_title>
  <official_title>Olmesartan Versus Nebivolol in Management of Hypertension in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-blind, randomized, active-treatment controlled clinical study evaluating the effect of
      omesartan and nebivolol versus no treatment on 24-hour brachial and central aortic blood
      pressure in hypertensive patients with acute ischemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 60 patients with hypertension and acute ischemic stroke (clinic BP &gt;160/100 mmHg
      and &lt;220/120 mmHg at day 3 of stroke onset) will be randomly allocated to therapy with
      olmesartan (20 mg/day) or nebivolol (5 mg/day) or no treatment between the 3rd to 7th day of
      hospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">August 20, 2019</completion_date>
  <primary_completion_date type="Actual">August 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between-group difference in change of 24-hour brachial BP</measure>
    <time_frame>Day 3 until Day 7 of stroke onset</time_frame>
    <description>24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 of stroke onset)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change of 24-hour pulse wave velocity</measure>
    <time_frame>Day 3 until Day 7 of stroke onset</time_frame>
    <description>24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 on stroke onset)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change of 24-hour augmentation index</measure>
    <time_frame>Day 3 until Day 7 of stroke onset</time_frame>
    <description>24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 on stroke onset)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in 24-hour central aortic BP</measure>
    <time_frame>Day 3 until Day 7 of stroke onset</time_frame>
    <description>24-hour ambulatory BP monitoring with the Mobil-O-Graph device (IEM, Germany) at baseline (Day 3 of stroke onset) and study-end (Day 7 on stroke onset)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antihypertensive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>At Day 4 of stroke onset, patients with clinic BP &gt;160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset</description>
    <arm_group_label>Olmesartan</arm_group_label>
    <other_name>No other intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>At Day 4 of stroke onset, patients with clinic BP &gt;160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>No other intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No antihypertensive treatment</intervention_name>
    <description>Patients will be left without treatment</description>
    <arm_group_label>No antihypertensive treatment</arm_group_label>
    <other_name>No other intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a first diagnosis of an acute ischemic stroke (permanent or transient)

          2. BP levels &gt;160/100mmHg at start of the third day of hospitalization

          3. BP levels &gt;160/100mmHg and &lt;220/120mmHg at start of the fourth day of hospitalization

        Exclusion Criteria:

          1. Patients with confirmed hemorrhagic stroke with computer tomography at hospital
             admission.

          2. Patients with chronic atrial fibrillation or other cardiac arrhythmia.

          3. Patients with BP levels &gt;220/120 mmHg during the hospitalization or patients with
             other hypertensive emergency situation (i.e. acute myocardial ischemia, aortic
             dissection, acute pulmonary edema, acute renal failure, hypertensive encephalopathy)
             which demands fast BP reduction with the use of intravenous antihypertensive drugs,
             according to current guidelines {Jauch, 2013 340 /id}.

          4. Patients with specific indication for treatment with blockers of the
             renin-angiotensin-aldosterone system (RAAS) other than hypertension (i.e., congestive
             heart failure, acute myocardial ischemia).

          5. Patients with specific indication for treatment with β-blockers other than
             hypertension (i.e., heart failure, tachyarrhythmia or angina pectoris).

          6. Patients with specific contra-indications for RAAS blockers (hyperkalemia, history of
             angioedema) and patients with a history of allergic reaction or severe hypotension
             after olmesartan treatment.

          7. Patients with specific contra-indications for β-blockers (heart rate &lt;60/min without a
             treatment with bradyarrhythmic drugs), chronic obstructive pulmonary disease or asthma
             and patients with history of allergic reaction after nebivolol treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni Georgianou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Lobanova I, Qureshi AI. Blood Pressure Goals in Acute Stroke-How Low Do You Go? Curr Hypertens Rep. 2018 Apr 10;20(4):28. doi: 10.1007/s11906-018-0827-5. Review.</citation>
    <PMID>29637385</PMID>
  </reference>
  <reference>
    <citation>Gąsecki D, Coca A, Cunha P, Hering D, Manios E, Lovic D, Zaninelli A, Sierra C, Kwarciany M, Narkiewicz K, Karaszewski B. Blood pressure in acute ischemic stroke: challenges in trial interpretation and clinical management: position of the ESH Working Group on Hypertension and the Brain. J Hypertens. 2018 Jun;36(6):1212-1221. doi: 10.1097/HJH.0000000000001704.</citation>
    <PMID>29621070</PMID>
  </reference>
  <reference>
    <citation>Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR.0b013e318284056a. Epub 2013 Jan 31.</citation>
    <PMID>23370205</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Vaios Vasileios</investigator_full_name>
    <investigator_title>Principal Investigator, Division of Nephrology and Hypertension, 1st Department of Medicine, AHEPA University Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

